undamentalytics Newsletter
Sign in

Madrigal Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Madrigal Pharmaceuticals, Inc.'s operations generated −$190m of cash; it spent $467,000 on capital projects, leaving free cash flow of −$190m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−54−22−26−42−158−184−225−324−456−190−157
Depreciation and amortisation10000001122
Stock-based pay331323212732508098134
Capital spending100000011012
Free cash flow−55−22−26−42−158−184−225−326−457−190−169
Free cash flow after stock pay−58−26−39−65−179−211−257−375−537−288−303
Share buybacks0——————————
Shares issued66——————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: INSM vs MDGLLKFT vs MDGLHALO vs MDGLALKS vs MDGL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Madrigal Pharmaceuticals, Inc.